Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPI-386 Nasal Gel for Motion Sickness in Seniors
NCT03988530Phase 3Completed
- Sponsor
- Defender Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Nov 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of scopolamine in motion sickness (2 arms), sponsored by Defender Pharmaceuticals. Primary endpoints: Incidence of subjects who developed motion sickness and requested further treatment and Safety of DPI-386 Nasal Gel compared to placebo nasal gel with an emphasis on cognitive adverse events. Started Jun 2019; status: completed.
02
Drugs
scopolamine
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT03988530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988530.